Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 09-2015 | 06-2015 | 03-2015 | 12-2014 | |
| Sales | 52,227 | 20,780 | 43,384 | 18,666 | 30,377 |
| Cost of Goods | 8,427 | 6,180 | 8,144 | 6,494 | 6,147 |
| Gross Profit | 43,800 | 14,600 | 35,240 | 12,172 | 24,230 |
| Operating Expenses | 38,762 | 38,017 | 31,153 | 26,577 | 28,228 |
| Operating Income | 5,465 | -23,237 | 4,231 | -13,911 | -3,851 |
| Interest Expense | 1,302 | 1,301 | 1,299 | 1,299 | 1,378 |
| Other Income | 155 | 78 | 87 | 102 | -45 |
| Pre-tax Income | 4,318 | -24,460 | 3,019 | -15,108 | -5,274 |
| Net Income Continuous | 4,318 | -24,460 | 3,019 | -15,108 | -5,274 |
| Net Income | $4,318 | $-24,460 | $3,019 | $-15,108 | $-5,274 |
| EPS Basic Total Ops | 0.04 | -0.19 | 0.02 | -0.12 | -0.05 |
| EPS Basic Continuous Ops | 0.04 | -0.19 | 0.02 | -0.12 | -0.04 |
| EPS Diluted Total Ops | 0.04 | -0.19 | 0.02 | -0.12 | -0.05 |
| EPS Diluted Continuous Ops | 0.04 | -0.19 | 0.02 | -0.12 | -0.04 |
| EBITDA(a) | $5,225 | $-22,684 | $4,849 | $-13,165 | $-2,998 |